<p>CureVac（納斯達克代碼：CVAC - 獲取免費報告）週一的盤中交易中股價上漲了 7.7%。該公司的股價最高達到 3.59 美元，最後交易價格為 3.48 美元。盤中交易期間大約有 269,297 股成交，較平均每日成交量 797,755 股下降了 66%。該股票之前收盤價為 3.23 美元。</p>
<h2>分析師評級變動</h2>
<ul>
<li>2 只小盤股在牛市中有望大放異彩</li>
</ul>
<p>另外，JMP 證券在 2 月 14 日的報告中重申了對 CureVac 的 “市場跑贏” 評級，並設定了 16.00 美元的目標價。</p>
<p><strong>獲取我們對 CVAC 的最新分析</strong></p>
<h2>CureVac 股價上漲 5.7%</h2>
<ul>
<li>3 只因 COVID 復甦而值得購買的股票</li>
</ul>
<p>該公司的 50 日簡單移動平均線為 3.04 美元，200 日簡單移動平均線為 3.18 美元。公司的流動比率為 6.20，速動比率為 6.19，債務股本比率為 0.05。公司的市值為 7.6611 億美元，市盈率為 6.21，貝塔值為 2.48。</p>
<p>CureVac（納斯達克代碼：CVAC - 獲取免費報告）最近在 4 月 10 日發佈了季度財報。該公司報告本季度每股收益（EPS）為（0.15 美元），低於市場共識預期的（0.14 美元）0.01 美元。該季度的收入為 1544 萬美元，而分析師預期為 640 萬美元。CureVac 的淨利潤率為 20.72%，股本回報率為 21.98%。分析師平均預測 CureVac 在當前財年將發佈 0.72 美元的每股收益。</p>
<h2>機構資金流入和流出</h2>
<p>一些對沖基金和其他機構投資者最近增加或減少了對 CVAC 的持股。法國巴黎銀行金融市場在第四季度新購入了 CureVac 的股份，價值約 58.5 萬美元。Two Sigma Investments LP 在第四季度購買了 CureVac 的新股份，價值約 39.1 萬美元。Alyeska Investment Group L.P.在第四季度將其在 CureVac 的持股增加了 25.0%。Alyeska Investment Group L.P.目前擁有 500,000 股該公司的股票，價值 170.5 萬美元，此前在上個季度又購買了 100,000 股。Jane Street Group LLC 在第三季度將其在 CureVac 的持股增加了 239.0%。Jane Street Group LLC 目前擁有 79,247 股該公司的股票，價值 23.5 萬美元，此前在上個季度又購買了 55,867 股。最後，Northern Trust Corp 在第四季度將其在 CureVac 的持股增加了 98.1%。Northern Trust Corp 目前擁有 60,100 股該公司的股票，價值 20.5 萬美元，此前在上個季度又購入了 29,759 股。機構投資者和對沖基金持有該公司 17.26% 的股份。</p>
<h2>關於 CureVac</h2>
<p>（獲取免費報告）</p>
<p>CureVac N.V.是一家生物製藥公司，專注於開發基於信使核糖核酸（mRNA）的各種變革性藥物。它正在開發預防性疫苗，例如針對 SARS-CoV-2 的 mRNA 疫苗候選者 CV2CoV，目前處於第一階段臨牀試驗；CV7202 用於狂犬病治療，亦處於第一階段臨牀試驗；以及用於治療多價季節性流感的 CVSQIV；Flu SV mRNA 用於治療核苷酸、單抗季節性流感。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過 CureVac</li>
<li>即將到來的 IPO 股票鎖定期，解讀</li>
<li>2025 年最佳防禦股票……到目前為止</li>
<li>如何使用股票篩選器尋找股票</li>
<li>Alphabet 在強勁財報和回購公告後反彈</li>
<li>投資優先股與普通股的比較</li>
<li>出售台積電會是巴菲特最大的遺憾嗎？</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 CureVac 1,000 美元嗎？</h2>
<p>在考慮 CureVac 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 CureVac 並不在名單上。</p>
<p>雖然 CureVac 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

CVAC

<p>CureVac（納斯達克代碼：CVAC）股價在午盤交易中上漲 7.7%，至 3.48 美元，交易量顯著下降。JMP Securities 維持 “市場表現優於大盤” 的評級，目標價為 16.00 美元。該公司報告的季度每股收益為（0.15 美元），未達到預期，但收入為 1544 萬美元，超出預期。CureVac 專注於基於 mRNA 的藥物，市值為 7.6611 億美元。機構投資者持有該股票的 17.26%。分析師預測當前財年的每股收益為 0.72</p>

<p>CureVac (NASDAQ:CVAC - Get Free Report)'s stock price was up 7.7% during mid-day trading on Monday . The company traded as high as $3.59 and last traded at $3.48. Approximately 269,297 shares traded hands during mid-day trading, a decline of 66% from the average daily volume of 797,755 shares. The stock had previously closed at $3.23.</p>
<div class="lb-trans"><p>CureVac（納斯達克代碼：CVAC - 獲取免費報告）週一的盤中交易中股價上漲了 7.7%。該公司的股價最高達到 3.59 美元，最後交易價格為 3.48 美元。盤中交易期間大約有 269,297 股成交，較平均每日成交量 797,755 股下降了 66%。該股票之前收盤價為 3.23 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>2 Small-Cap Stocks Set to Shine in a Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只小盤股在牛市中有望大放異彩</li>
</ul>
</div><p>Separately, JMP Securities reiterated a &#34;market outperform&#34; rating and set a $16.00 price target on shares of CureVac in a report on Friday, February 14th.</p>
<div class="lb-trans"><p>另外，JMP 證券在 2 月 14 日的報告中重申了對 CureVac 的 “市場跑贏” 評級，並設定了 16.00 美元的目標價。</p>
</div><p><strong>Get Our Latest Analysis on CVAC</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 CVAC 的最新分析</strong></p>
</div><h2>CureVac Trading Up 5.7 %</h2>
<div class="lb-trans"><h2>CureVac 股價上漲 5.7%</h2>
</div><ul>
<li>3 Stocks to Buy For the COVID Resurgence</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只因 COVID 復甦而值得購買的股票</li>
</ul>
</div><p>The business has a 50 day simple moving average of $3.04 and a two-hundred day simple moving average of $3.18. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The company has a market cap of $766.11 million, a PE ratio of 6.21 and a beta of 2.48.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為 3.04 美元，200 日簡單移動平均線為 3.18 美元。公司的流動比率為 6.20，速動比率為 6.19，債務股本比率為 0.05。公司的市值為 7.6611 億美元，市盈率為 6.21，貝塔值為 2.48。</p>
</div><p>CureVac (NASDAQ:CVAC - Get Free Report) last posted its quarterly earnings results on Thursday, April 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The business had revenue of $15.44 million during the quarter, compared to analysts' expectations of $6.40 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%. On average, analysts forecast that CureVac will post 0.72 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CureVac（納斯達克代碼：CVAC - 獲取免費報告）最近在 4 月 10 日發佈了季度財報。該公司報告本季度每股收益（EPS）為（0.15 美元），低於市場共識預期的（0.14 美元）0.01 美元。該季度的收入為 1544 萬美元，而分析師預期為 640 萬美元。CureVac 的淨利潤率為 20.72%，股本回報率為 21.98%。分析師平均預測 CureVac 在當前財年將發佈 0.72 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CVAC. BNP Paribas Financial Markets acquired a new position in shares of CureVac during the fourth quarter worth about $585,000. Two Sigma Investments LP purchased a new stake in CureVac during the 4th quarter worth approximately $391,000. Alyeska Investment Group L.P. boosted its stake in shares of CureVac by 25.0% during the 4th quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company's stock valued at $1,705,000 after buying an additional 100,000 shares during the last quarter. Jane Street Group LLC grew its position in shares of CureVac by 239.0% during the third quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock worth $235,000 after buying an additional 55,867 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in CureVac by 98.1% in the fourth quarter. Northern Trust Corp now owns 60,100 shares of the company's stock valued at $205,000 after acquiring an additional 29,759 shares in the last quarter. Institutional investors and hedge funds own 17.26% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近增加或減少了對 CVAC 的持股。法國巴黎銀行金融市場在第四季度新購入了 CureVac 的股份，價值約 58.5 萬美元。Two Sigma Investments LP 在第四季度購買了 CureVac 的新股份，價值約 39.1 萬美元。Alyeska Investment Group L.P.在第四季度將其在 CureVac 的持股增加了 25.0%。Alyeska Investment Group L.P.目前擁有 500,000 股該公司的股票，價值 170.5 萬美元，此前在上個季度又購買了 100,000 股。Jane Street Group LLC 在第三季度將其在 CureVac 的持股增加了 239.0%。Jane Street Group LLC 目前擁有 79,247 股該公司的股票，價值 23.5 萬美元，此前在上個季度又購買了 55,867 股。最後，Northern Trust Corp 在第四季度將其在 CureVac 的持股增加了 98.1%。Northern Trust Corp 目前擁有 60,100 股該公司的股票，價值 20.5 萬美元，此前在上個季度又購入了 29,759 股。機構投資者和對沖基金持有該公司 17.26% 的股份。</p>
</div><h2>About CureVac</h2>
<div class="lb-trans"><h2>關於 CureVac</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.</p>
<div class="lb-trans"><p>CureVac N.V.是一家生物製藥公司，專注於開發基於信使核糖核酸（mRNA）的各種變革性藥物。它正在開發預防性疫苗，例如針對 SARS-CoV-2 的 mRNA 疫苗候選者 CV2CoV，目前處於第一階段臨牀試驗；CV7202 用於狂犬病治療，亦處於第一階段臨牀試驗；以及用於治療多價季節性流感的 CVSQIV；Flu SV mRNA 用於治療核苷酸、單抗季節性流感。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than CureVac</li>
<li>Upcoming IPO Stock Lockup Period, Explained</li>
<li>Best Defense Stocks in 2025... So Far</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>Alphabet Rebounds After Strong Earnings and Buyback Announcement</li>
<li>Investing In Preferred Stock vs. Common Stock</li>
<li>Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 CureVac</li>
<li>即將到來的 IPO 股票鎖定期，解讀</li>
<li>2025 年最佳防禦股票……到目前為止</li>
<li>如何使用股票篩選器尋找股票</li>
<li>Alphabet 在強勁財報和回購公告後反彈</li>
<li>投資優先股與普通股的比較</li>
<li>出售台積電會是巴菲特最大的遺憾嗎？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CureVac Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 CureVac 1,000 美元嗎？</h2>
</div><p>Before you consider CureVac, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CureVac 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 CureVac 並不在名單上。</p>
</div><p>While CureVac currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CureVac 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

CureVac（NASDAQ 代碼：CVAC）股價上漲 7.7% - 是否仍然值得買入？